| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
CNX-419 hydrobroMide manufacturers
|
| | CNX-419 hydrobroMide Basic information |
| Product Name: | CNX-419 hydrobroMide | | Synonyms: | AVL-301 hydrobroMide;CNX-419 hydrobroMide;CO-1686 (hydrobroMide);CO-1686 HBr salt,Rociletinib HBr salt;AVL-301 HBr salt, CNX-419 HBr salt;Rociletinib (CO-1686,AVL-301) HBr;CNX-419 HBr;CO-1686 HBr | | CAS: | 1446700-26-0 | | MF: | C27H29BrF3N7O3 | | MW: | 636.47 | | EINECS: | | | Product Categories: | | | Mol File: | 1446700-26-0.mol |  |
| | CNX-419 hydrobroMide Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : ≥ 59 mg/mL (92.70 mM) | | form | Solid | | color | Light yellow to yellow |
| | CNX-419 hydrobroMide Usage And Synthesis |
| Uses | Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively. | | in vivo | Rociletinib (100 mg/kg/day, p.o.) demonstrates anti-tumor activity in NSCLC EGFR mutant xenograft models. Rociletinib (50 mg/kg bid, p.o.) demonstrates anti-tumor activity in human EGFR-L858R and EGFR-L858R-T790M expressing transgenic mice[1]. | | IC 50 | EGFRL858R/T790M: 21.5 nM (Ki); EGFRT790M: 303.3 nM (Ki) | | References | [1] Walter AO, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Sep 25. DOI:10.1158/2159-8290.CD-13-0314 |
| | CNX-419 hydrobroMide Preparation Products And Raw materials |
|